
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is well positioned to maintain steady ~MSD% growth through its base clinical services business, driven by a rapidly growing NGS segment and new test launches. The company also has potential drivers for margin improvement and favorable outcomes from patent litigation, posing upside potential for investors. Additionally, NEO's relationships with community hospitals and expansion of its test menu make it an attractive player in the cancer testing space.
Bears say
NeoGenomics is expected to see slower revenue growth of 7% or less due to smaller than expected market share gains, slower test menu expansion, and potential pricing cuts to Medicare-reimbursed tests. Additionally, competition in NGS and informatics could limit growth in their legacy testing modalities. These factors contribute to the negative outlook on the stock, with a bear case scenario suggesting a potential price target of $7.00 based on an EV/sales multiple of 1.5x their estimated 2026 sales and a base case 12-month price target of $14.00 based on an EV/sales multiple of 2.5x their estimated 2026 sales.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares